Genome-wide analysis of pleiotropic and functional variants across three age-related ocular disorders

Xuemin Yao[1], Hongxi Yang[2], Han Han[1], Xuejing Kou[1], Menghan Luo[3], Yao Zhou[3], Jianhua Wang[3], Xutong Fan[3], Xiaohong Wang[2,*], Mulin Jun Li[2,3,*], Hua Yan[1,*]

[1]Department of Ophthalmology, Tianjin Medical University General Hospital, Tianjin, China.
[2]Department of Pharmacology, Tianjin Key Laboratory of Inflammation Biology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China.
[3]Department of Bioinformatics, The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China.

*Correspondence: xiaohongwang@tmu.edu.cn (X.W.), mulin@tmu.edu.cn (M.J.L.), zyyyanhua@tmu.edu.cn (H.Y.)

Abstract

Purpose: Genome-wide association studies (GWAS) have revealed plenty of putative loci of ocular disorders, and the relationship among ocular disorders manifesting vision loss has been widely studied. However, genetic pleiotropy correlations remain unknown in eye diseases.

Methods: The GWAS summary statistics of age-related macular disorder (AMD), cataract and glaucoma were leveraged to dissect the genetic pleiotropy from three aspects: genomic pleiotropy, regional pleiotropy and variant-level pleiotropy. A meta-analysis using three approaches was performed. Cell types related to disease risk were unveiled using retina and anterior chamber angle single cell RNA (scRNA) seq profiles and retina single cell ATAC (scATAC) seq data. Causal pleiotropic genes of the above three diseases were prioritized base on the colocalization between retina-specific/cell-type-specific annotations and credible sets. In addition, we assessed the protein-protein network of candidate causal genes as well as the druggability.

Results: Genetic correlations were corroborated and eleven pleiotropic regions were identified between the pairs of AMD, cataract and glaucoma. Ten pleiotropic loci were jointly identified, including three pleiotropic loci intersecting with retina-specific eQTL SNPs and enhancer regions as well as six pleiotropic loci resided in HiChIP loops or cell-type-specific peaks. Six loci were replicated using the Finggen GWAS data of corresponding diseases. Müller cell, astrocyte, vascular endothelium and fibroblast were identified in cell-type trait association analysis. Through the strategy we have formulated, thirty genes causally associated with three traits were prioritized, which enriched in the pathways of nerve development and cell communication.

Conclusions: The genetic pleiotropy of AMD, cataract and glaucoma was detailedly characterized in our study which provides potential drug targets for ocular disorders.

Introduction

Genome-wide association studies (GWASs) have identified enormous potential genetic variants in ocular diseases, especially with complex pathogenesis and severe clinical outcomes, and these studies indicated that the majority of ocular traits are highly polygenetic which means the phenotype are decided on various variants. Pleiotropy denoted one gene or variant that affects different traits[1]. The pleiotropy of ocular diseases has been interrogated between eye indicators or other organ diseases as multiple systematic works concluded[2-7]. For example, a significant inverse correlation between central corneal thickness and keratoconus was unveiled using the risk variants[8]. Grassmann et. al. calculated the genetic scores between age-related macular degeneration (AMD) and several complex diseases and discovered AMD was associated with reduced risk for cardiovascular diseases, increased risk for autoimmune diseases and so on[9].

Here we focused on three age-related diseases with high heritability, ranging from 0.35 to 0.81[10-13]: AMD, cataract and glaucoma. AMD is one of the leading causes of vision loss in worldwide elder adults, the overall prevalence of AMD among 70-year-olds or older is 13.2% for early AMD and 3.0% for late AMD [14,15], a previous study analyzing 16,144 patients and 17,832 controls genotype data has been identified 52 significant SNPs in 34 loci [16]. Cataract which affects about 95 million people remains the foremost reason for blindness in middle-income and low-income countries[17]. Recently, a multiethnic GWAS meta-analysis of cataract combined the Genetic Epidemiology Research in Adult Health and Aging (GERA) and the UK Biobank (UKBB) cohorts and prioritized 54 genome-wide significant loci[18]. Glaucoma is the most widespread cause of irreversible blindness globally with roughly 3·5% global prevalence for people aged 40–80 years[19,20], 112 genomic loci were revealed through a joint analysis of 139,555 European participants with raised intraocular

pressure, one of the most nontrivial risk factors for glaucoma[21] and 127 open-angle glaucoma loci were indentified in a multiethnic study[22]. Genetic correlation among AMD, cataract and glaucoma has been rigorously examined in terms of case-control studies and GWASs, however, such studies remain narrow in focus on the estimation of genetic correlation rather than the pleiotropic genes[23-25].

Albeit substantial pleiotropic loci were found in ocular diseases or other diseases,, most of the detective genes were not truly causal. It takes great effort to pinpoint causal genes of pleiotropic loci due to the extensive linkage disequilibrium (LD) in the human genome and genetic variation of different cell types and tissue in other diseases. Usually, the common resolution is to map the gene with cell-type-specific or tissue-specific eQTL data and epigenetic data. With the lower cost and accuracy improvement of sequencing methods, integrating large tissue and cell-specific data with ocular trait GWAS data sets seems to be achievable, for example, Ratnapriya R et. al. generated a cis-eQTL dataset of postmortem retinas and ascertained causal genes at six loci of AMD[26]. Similarly, a recent analysis identified 15 putative causal genes for AMD via colocalization analysis for AMD risk SNPs and eye eQTL SNPs in terms of the eQTL database containing macula-specific retina and retinal pigmented epithelium (RPE) /choroid, which was built utilizing the RNA-seq profiles of 129 donors[27]. To understand which cell type is more likely to contribute to glaucoma pathogenesis, scRNA-seq analyses of the aqueous humor outflow pathways in humans were conducted gradually, generating multiple cell atlas for the tissue, and then genes implicated in GWAS loci for glaucoma risk were localized to the atlas to decipher the expression of genes in different cells[28]. Consistent with another scRNA-seq analysis study of outflow tissues[29], most glaucoma-relevant genes were highly expressed in trabecular meshwork cell types. Similarly, cell-type trait association analysis

have been carried out to verify the accuracy of the prediction of preferential expression, for instance, glia, vascular cells and cone photoreceptors were unveiled to be associated with AMD based on GWAS summary statistics and single-cell transcriptomic atlas of the human retina[30]. Besides, global decreases in chromatin accessibility were reported in the RPE with AMD using ATAC seq. Genes relevant to differentially accessible regions in various cell types show altered expression in AMD which may result in dysfunction of RPE and visual impairment[31]. Together, these studies indicate that integration analysis of multi-omics data at the cell/tissue level will be beneficial to select the risk genes, facilitating the discovery of novel effective treatments.

Here, we curated the largest GWAS summary statistics of genetically complex ocular diseases of AMD, cataract and glaucoma and carried out a meta-analysis with three different methods, totally identifying ten pleiotropic loci. Afterward, to better understand the genetic architecture of ocular disease, we integrated the GWAS data with eye-specific cell/tissue eQTL and epigenetic data to prioritize the causal genes. Drug repurposing was subsequently conducted utilizing curated risk genes for future treatment or prevention of disease.

Results

Genetic sharing and pleiotropy architecture across AMD, cataract and glaucoma

First, we used the UKBB individual data to analysis the correlation between AMD, glaucoma and cataract which showed positive correlation among these diseases. To delineate the shared genetic architecture among the three age-related ocular disorders, we firstly collected the GWAS summary statistics of AMD, cataract and glaucoma hitherto from public resources(Supplementary table1). In the light of the signal overlaps of the three ocular GWAS summary statistics (**Supplementary Figure 1a**), genetic correlations were measured using LD Score regression (LDSC) [32] and SumHer

LDAK-Thin [33] models. We observed moderate and concordant genome-wide genetic correlation among these traits after careful quality control (**Figure 1b, 1c, Supplementary Figure X and Supplementary Table SX**), in which glaucoma-cataract and AMD-cataract shows positive genetic correlation, while AMD-glaucoma exhibit negative genetic correlations. The positive genetic correlation between AMD and glaucoma were reported in a previous work which is not consistent with our gene correlation results due to environment affect or inadequate power[23]. To sum up, these new finding based on genetic evidence as well as epidemiological associations suggest the latent correlation between these ocular traits. Besides, multiple bi-directional MR methods were applied to each pair of diseases to assess whether shared genetic components was coherent with true pleiotropy or mediated pleiotropy. Presuming consistent results in three of five MR methods means a strong causal effect between two traits, there is no or weak evidence for potentially causal relationships among AMD, cataract and glaucoma (**Supplementary Figure X**).

Cross-disorder meta-analysis reveals 10 pleiotropic loci

Considering the indication for genetic relationships between AMD-cataract, AMD-glaucoma and cataract-glaucoma, 11 pleiotropic regions (posterior probability associated with two phenotypes > 0.6) were identified in disease pairs using GWAS-pw, one of which (chr9:20464018-2220526) turned out to be significant of three diseases revealed by two tests (**Figure 1b, Supplementary Table X**). Notably, four regions (chr5:87390784-88891173, chr9:20464018-2220526, chr11: 87430571- 89208854, chr15:110336875-113261782) which overlapped with five pleiotropic loci identified by meta-analysis (see below) also reached the threshold in the joint phenotypes (**Figure 1b**).Next, we curated the largest GWAS summary statistics of AMD, cataract and glaucoma

containing 257718 cases and 560421 controls of European ancestry in total (AMD: 14,034 cases and 91,214 controls, cataract: 11,306 cases and 349,888 controls, glaucoma: 232,378 cases and 119,319 controls) and conducted cross-trait meta-analyses using three complementary methods with about 1.57 million SNPs, and only those SNPs that surpassed genome-wide significance (P-value < 5×10^{-8}) and had influences on at least two traits were reserved. For ASSET, two patterns were supported and both were performed that one-sided ASSET meta-analysis maximized the standard fixed-effect meta-analysis test-statistics over all possible subsets and guaranteed identification of pleiotropic loci that have associations in the same direction while two-sided ASSET meta-analysis in two-directions automatically. Accordingly, we identified 5, 10, 15 and 7 pleiotropic loci through three software METAL, one-sided ASSET, two-sided ASSET and pleioFDR respectively under the condition that genomic inflation factor did not deviate obviously from one. Guaranteeing the lead SNPs were slightly significant in all primary GWAS summary statistics, ten pleiotropic loci were conservatively prioritized to be the causal loci which the one-sided ASSET results overlapped with the other three approaches (**Table X, Figure 2a, Figure S2, Figure S3, Figure S4**). . Most signals were significantly associated with glaucoma and the other disease had a weak signal that makes the signal even stronger. Then, four loci became significant as the sample size increased. One of these loci physically intersected with a pleiotropic region related to AMD and glaucoma (**Table 1, Figure 1b**) which makes our results convictive. Furthermore, we curated additional GWAS datasets of AMD, cataract and glaucoma from FinnGen and conducted a meta-analysis with ASSET, four loci (lead SNPs: rs12670840, rs944801, rs1619882 and rs1129038) were replicated if the P-value of any SNP in the same loci was smaller than 1×10^{-5} in the one-sided ASSET or two-sided ASSET results.

Integrative single cell analysis identifies likely causal cell types of ocular comorbidity

Due to the existence of cellular genetic heterogeneity, how the pleiotropic loci affect the gene expression in specific ocular cell types of disease needs to be figured out, we obtained seven scRNA seq data and one scATAC seq derived from 33 human eyes including a recent data to interpret the loci with ocular cell/tissue functional annotations and connect pleiotropic variants to causal genes properly and appropriately, and performed cell-type trait association analysis to explore most likely cell types whose gene signatures correlate with genetic risk (**Table S2**). In total, over forty cell types across anterior chamber angle and retina/choroid were utilized in our study. Müller cells and astrocytes were observed as predictive cell types of ocular disease risk in MAGMA and LDSC. (**Figure 2b, Table X**). Although there are few studies on the relationship between the two cell types and the diseases, both are immune-related cells indicating that immune defense can be activated in disorder pathogenesis. Besides, the vascular endothelium and fibroblast also show the genetic correlation in two or more MAGMA analyses (FDR < 0.05, **Figure S5**) which was consistent with the previous studies[30,34,35].

Functional prioritization of causal pleiotropic variants and their target genes

Then, we obtained two public retinal cis-eQTL data and conducted colocalization analyses with R package COLOC in 10 pleiotropic risk loci to prioritize eGenes. We found rs3766916 intersected with one or six eGenes residing in the ±1MB region of lead SNPs (**Figure 2b**, **Figure SX**, **Table SX**). In agreement, epigenetic modifications were broadly involved in gene expression regulation and the changes of epigenetic modification may be deleterious to the body. To dissect eye epigenetics for variant annotation, ATAC-seq data and acetylated histone H3 lysine 27 (H3K27ac) ChIP-Seq data of three retinal samples were imported into the ABC model separately, predicting

37877, 43328, 39187 retinal-specific enhancer regions in the whole genome (**Table X**). We then leveraged the Susie of PolyFun to pinpoint the 95% credible sets of 10 pleiotropic loci and annotated them with the ocular eQTL SNPs, epigenetics comprehensively. As a result, we identified 30 causal genes relevant to AMD, cataract and glaucoma according to the strategy mentioned in the method part (**Table S8**). Three pleiotropic loci colocalized with HiChIP loops as well as four loci located in predicted enhancer regions or Müller cell/astrocyte open chromatin peaks.

SNP rs3766916, one SNP in the credible set of chromosome one, turned out to be a causal eQTL variant targeting several genes like *TRIM46* and *GON4L* (**Figure 2c, Figure SX**). *TRIM46* encodes a protein of the tripartite motif family which can control neuronal polarity and high-glucose-induced ferroptosis of human retinal capillary endothelial cells[36]. Interestingly, we found SNP rs4845712 that in high LD with SNP rs3766916 may more likely be causal SNP since the highest posterior probability and overlap with H3K27ac HiChIP loop as well as ABC model enhancer (**Figure 2d**). *EFNA4* has been reported to inhibit axonal regeneration and regulate axon guidance in optic nerve[37,38]. *CKS1B* encodes proteins binding to the catalytic subunit of the cyclin dependent kinases and the proliferation and migration of retinoblastoma cells can be restrained by suppressing the expression of *CKS1B*[39].

Another SNP rs10898526 located in a locus prioritized by three meta-analysis methods also targeted the predicted enhancer. SNP rs10898526 overlaps with astrocyte and Müller cell specific peak which targeted gene *ME3*, indicating that this SNP may alter the *ME3* in astrocytes and Müller cells and contribute to the pathogenesis of these ocular traits (**Figure 3a**). *ME3*, a gene involved in the oxidative decarboxylation of malate to pyruvate, was significantly implicated in glaucoma GWAS and macular thickness[21,40]. On the other hand, a pleiotropic SNP rs351973 with a causal role

overlapped with one of the *PTBP1* enhancer regions (**Figure 3b**), suggesting that rs17337621 may modulate these eye disorders by interacting with *KISS1R* and *R3HDM4*. There are few studies about the relationship between both genes and ocular diseases while *PTBP1* was reported in previous studies.The *PTBP1* belongs to the subfamily of ubiquitously expressed heterogeneous nuclear ribonucleoproteins (hnRNPs), which bind to pre-mRNAs in the nucleus and influence pre-mRNA processing and other aspects of mRNA metabolism and transport. Knockdown of *Ptbp1* in mice induced the conversion of Müller glia into retinal ganglion cells (RGCs) effectively, resulting in the alleviation of disease symptoms pertinent to RGC loss[41]. -Briefly, our results highlighted and approved the importance and necessity of tissue-specific annotations for mapping GWAS significant variants to potential gene targets.

Shared biological pathway and drug repurposing opportunity

To assess the molecules with impact on the biological pathways relevant to ocular diseases and explore the potential role of candidate genes in drug repurposing, the implementation of network is a valuable scheme to prioritize potential genes. GO pathway analysis was conducted in three orthogonal ontologies: molecular function, biological process and cellular component, to explore the biological mechanism of causal genes of diseases. We detected 47 significant (FDR < 0.05) GO pathways including regulation of nerve development (GO:0021675, GO:0007409 and GO:0048666) which has been widely studied in the pathogenesis of AMD and glaucoma (**Figure 4a, 4b, Table X**)[42-44]. Conspicuously, multiple protein modification pathways were also enriched such as regulation of protein modification process (GO:0031399, FDR = 0.0043), protein phosphorylation (GO:0006468, FDR = 0.0264) and histone h3 acetylation (GO:0043966, FDR = 0.0385). *EFNA3*,

EFNA4 and *SHC1* were hub genes in the protein-protein network of causal genes (**Figure 4b**). We conducted gene-phenotype relationship analysis using the Enrichr, and the causal gene set was enriched in skin/hair/eye pigmentation (q-value = 0.0236) and eye color (q-value = 0.0008). Thenwe linked genes to licensed drugs and found aspirin and zopiclone targeting causal genes *ME3* and *GABRA5* separately. We searched the approved drugs for AMD, cataract and glaucoma in Drugbank and nominated 88 disease drug targets in DGIdb. Though none of the risk genes was consistent with the pharmacological targets, 12 of the 30 causal genes (40%) were found encoding proteins interacting with disease drug targets. Noteworthily, gene *EFNA4* , one gene involved in the neuron development in previous pathway analysis, interacted with aflibercept targeted gene *VEGFA* and pilocarpine targeted gene *NTRK1* in the PPI network of AMD and glaucoma drug targeted genes(**Figure 4c, Figure 4d**), further investigations need to be conducted necessarily.

Discussion

In our study, we first comprehensively confirmed the relationship between AMD, cataract and glaucoma using epidemiological association tests, genetic correlation analysis and Mendelian randomization, then we implemented pleiotropic region analysis to explore the regional pleiotropy. Ten significant pleiotropic loci of AMD, cataract and glaucoma were identified leveraging meta-analysis including six loci achieved marginal significant threshold in replication meta-analysis. To reveal the impact of these genetic fundings on traits, we acquired the eye-specific eQTL data to prioritize the causal genes of pleiotropic loci more accurately. Besides, we disclosed Müller cell and astrocyte as the disease-associated cell types and predicted the enhancer regions with retinal epigenetic data. We assigned the annotations we got to credible sets and identified 30 causal genes.

The interrogation of network biology was implemented to capture the GWAS-associated molecules and pathways for drug development. In conclusion, our study indicated these genes may play a more extensive role during the onset of the disease and may expand the horizon of disease treatment.

There is no doubt that understanding the trait-related cell types is of great benefit for the disease pathogenesis. We revealed Müller cells and astrocytes as potential risk cell types for AMD, cataract and glaucoma through two different software calculations. A study claimed that Müller cells play a role in regulating the serine biosynthesis, a critical part of the macular defense against oxidative stress and dysregulation may cause macular lesions.[45] And Müller cells and astrocytes have multiple functions symbiotically associated with retinal ganglion cells such as glutamate clearance, neurotrophic factors release and neurotransmitters recycle[46]. Another analysis reported that the loss of astrocyte, together with retinal ischemia occurred in AMD macula, could induce the death of the ganglion cells owing to the reduction against oxidative damage[47]. Despite the insufficient evidence in our study, the connection between vascular endothelium and these ocular diseases has been wildly discussed[48-52]. As a matrix cell type, fibroblast can be activated by matricellular proteins resulting in abnormal fibrotic processes extracellular matrix and subsequent elevatory intraocular pressure[34]. In addition, fibroblasts may be recruited to neovascular lesions and differentiate to myofibroblasts, the key cell type in macular fibrosis secondary to neovascular AMD[35].

There are a few shortcomings in these analyses,, the case number of glaucoma was much larger than the other two diseases and some control may inevitably overlap in glaucoma and cataract , which may affect the power of signals and cause system error in meta-analysis. We found several cell types related to these traits in our study. But based on limited public annotation data, tissue level annotation profiles were leveraged rather than cell-type specific data to identify truly causal genes.

Thus, the genetic information of the eye needs to be interpreted more precisely and more accurately. Second, fine-mapping only yields credible sets of variants that contain potential causal variants by estimating the probability of causality, so prioritized genes may not be true causal genes. In addition, though we found some drugs targeted the disease-risk genes we found, whether these drugs are beneficial or harmful to the phenotype is still unknown. More experiments of drug discovery and repurposing need to be conducted for future treatment.

Methods

Data collection

GWAS summary statistics of European ancestry with the largest sample size were obtained searched from eight databases (including GWAS Catalog[53], UK Biobank[54], GeneATLAS[55], GWAS Atlas[2], LD Hub[56], GRASP[57], PhenoScanner[58], dbGap[59]). GWAS summary statistics with available signed statistics (beta or odds ratio), branded effect alleles, non-effect alleles were completely retained during searching. The replication GWAS data were curated from FinnGen[60]. More detailed information of GWAS summary statistics for AMD, cataract, glaucoma is shown in **Table S1**.

Estimation of genetic correlation

Using GWAS summary statistics derived from above datasets with sample size larger than 50000 and the quantity of cases and controls lager than 10000, we conducted the LD Score regression (LDSC)[32] of these ocular diseases to estimate the genetic correlation between each other. SNPs were filtered to HapMap3 SNPs to avoid bias from inconstant imputation quality. Besides, SNPs with INFO <= 0.9, MAF <= 0.01, variants that are not SNPs, strand ambiguous SNPs and SNPs with duplicated rs numbers were removed. Pre-computed LD scores and regression weights for 1000G

European populations were downloaded from the LDSC website (http://www.broadinstitute.org/~bulik/eur_ldscores/). We carefully ensured the LD Score regression intercepts of AMD, cataract and glaucoma were close to 1 during estimation. Moreover, the genetic correlations of these diseases were confirmed using another software called SumHer from LDAK[33] with recommended LDAK-Thin model. The tagging file computed using 2000 white British individual genetic data files were downloaded from the LDAK website (https://dougspeed.com/pre-computed-tagging-files/) and the cutoff was set to 0.01 to preclude large-effect loci which explain at least 1% of phenotypic variance.

Mendelian randomization

Mendelian randomization (MR) analysis between two traits was operated to determine whether genetic correlations were due to a causal link or confounding factors by R package TwoSampleMR[61] which encompasses five MR methods (MR Egger, Weighted median, Inverse variance weighted, Simple mode, weighted mode). The instruments of each exposure trait were the significant SNPs (P-value < 5e-8) after clumping while the instruments of each outcome trait were all SNPs. Variants without rs numbers were annotated by the dbSNP[62] database otherwise SNPs were removed during the subsequent analysis of this study.

Determination of pleiotropic regions

We performed pleiotropic region analysis utilizing gwas-pw[63], a tool for jointly analyzing pairs of GWAS traits. The overlapped SNPs of both traits were split into multiple blocks based on the bed files available from https://bitbucket.org/nygcresearch/ldetect-data. Separately, gwas-pw reckoned the posterior probability of four models that the pleiotropic region 1) associated only to phenotype 1, 2) associated only to phenotype 2, 3) associated to both phenotypes, 4) associated to both

phenotypes independently.

Identification of pleiotropic loci

To identify the pleiotropic SNPs and characterize the pleiotropy at a single variant level, cross-trait meta-analysis was carried out with GWAS summary statistics of three ocular diseases using three different approaches:1) ASSET[64]; 2) METAL[65]; 3) pleioFDR[66]. The ASSET explored all possible subsets of traits and evaluated fixed-effect meta-analysis for each subset. The default scheme was selected when executing the METAL with the correction of sample overlap. The pleioFDR leverages overlapping SNP associations of related phenotypes to identify the genetic pleiotropic loci. All significant SNPs into two or more traits were sustained to the following analysis. Once the significant SNPs were classified, we conducted variant clumping through Plink[67] and merged pleiotropic loci if they physically overlap (±250kb). The summary statistics of these diseases were standardized with a downloaded reference derived from genome files for 22 autosomes of filtered 1000G[68] European ancestry samples.

Cell-type trait association analysis

We applied MAGMA[69] to evaluate whether specific ocular cell types showed significant heritability enrichment for traits based on the ASSET one-sided summary statistics. MAGMA also needs gene average expression across cell types derived from the single-cell RNA-seq (scRNA-seq) data of anterior chamber angle and retina/choroid[27-30,49,70] (**Table S2**). We additionally downloaded the raw data and figured out the average expression per cell type for each dataset through Cell Ranger[71] and R package Seurat[72] unless the information is available in ref supplementary files. Cell types were assigned with the gene marker mentioned in the ref and the same cell types were renamed manually to keep in concordance within different scRNA-seq data. Gene names were all transferred to Entrez

gene ID leveraging the R package biomaRt[73]. We appointed the direction of testing to "greater" and selected the condition-hide modifier for cell-type trait association analysis. Then we leveraged the open chromatin peaks of retinal cell types from scATAC seq to estimate LD scores for LDSC and conducted the cell-type trait association analysis.

Fine mapping of pleiotropic loci

The colocalization analysis between two eye eQTL data[26,74] and ASSET one-sided GWAS data was conducted using R package COLOC[75]. We then picked out SNPs that had H4 posterior probability larger than 0.75, GWAS P-value smaller than 1×10^{-6} and eQTL P-value smaller than 0.05 in pleiotropic loci. Through utilizing three retina sample ATAC seq data and H3K27ac ChIP seq data[76], genomic enhancer regions of the retina were predicted by Activity-by-Contact (ABC) model[77] with the default threshold. The overrepresented sequences and adaptor were trimmed by TrimGalore (https://github.com/FelixKrueger/TrimGalore) and the FastQ files were aligned by Bowtie2[78]. Next, we profiled the causal SNPs through fine mapping of pleiotropic loci revealed by the above three meta-analysis methods. The one-sided ASSET meta-analysis results of pleiotropic SNPs located in the ±1MB region of lead SNPs with $P < 1\times10^{-4}$ were imported into PolyFun[79] fine-mapping with a statistical embedded method called Susie[80], and 95% credible sets were revealed assuming one causal SNP in one locus. SNPs were included in the credible sets until the sum of posterior probability was larger than 0.95. And the causal genes in a pleiotropic locus were confined with the following rules: 1) Whether the locus contains eye eQTL SNPs or not? If yes, the eQTL harboring genes (eGenes) were picked out. 2) Whether the locus located in the open chromatin peaks from a public retina HiChIP data? If yes, the causal genes were anchor targeted genes. 3)Whether the locus has a genomic region overlap with the ABC model enhancer region or cell-type specific peak? If

yes, the causal genes were enhancer target genes or peak-nearest genes. 4)If the pleiotropic locus contained none of eQTL SNP or mapped within any enhancer region, the nearest gene of SNP with the largest COLOC posterior probability was identified as causal genes. Moreover, gene ontology (GO) pathway enrichment analysis of causal genes with no more than 10 interactors was conducted in STRING[81] to shed light on pathogenic biological processes.

Drug repurposing

We curated the approved drugs targeted at pleiotropic causal genes and target genes of the drug for AMD, cataract and glaucoma in Drugbank[82] and DGIdb[83] to verify if the risk genes were partially same as drug target genes. The protein-protein interaction (PPI) network information was obtained from STRING and depicted by Cytoscape[84] to evaluate the potential relationship between pleiotropic causal genes and target genes.

Acknowledgements

Funding

This study was supported by the National Natural Science Foundation of China (Grant Numbers 82020108007, 81830026, 32070675) and the Beijing-Tianjin-Hebei Special Project [Grant Number 19JCZDJC64300(Z), 20JCZXJC00180].

Competing interests

The authors declare no conflict of interest.

Contributions

H.Y. and M.J.L. conceived of the project. X.Y. performed the analyses. XXXXX contributed the data collection and processing. XXXX contributed to manuscript polishing and provided analysis suggestions. X.Y., M.J.L. and H.Y. wrote the manuscript. The authors read and approved the final submission.

Reference

1 Solovieff, N., Cotsapas, C., Lee, P. H., Purcell, S. M. & Smoller, J. W. Pleiotropy in complex traits: challenges and strategies. *Nature reviews. Genetics* **14**, 483-495, doi:10.1038/nrg3461 (2013).

2 Watanabe, K. *et al.* A global overview of pleiotropy and genetic architecture in complex traits. *Nature genetics* **51**, 1339-1348, doi:10.1038/s41588-019-0481-0 (2019).

3 Fan, Q. *et al.* Genome-wide association meta-analysis of corneal curvature identifies novel loci and shared genetic influences across axial length and refractive error. *Communications biology* **3**, 133, doi:10.1038/s42003-020-0802-y (2020).

4 Iglesias, A. I. *et al.* Determining Possible Shared Genetic Architecture Between Myopia and Primary Open-Angle Glaucoma. *Investigative ophthalmology & visual science* **60**, 3142-3149, doi:10.1167/iovs.18-26231 (2019).

5 Simcoe, M. J., Khawaja, A. P., Hysi, P. G. & Hammond, C. J. Genome-wide association study of corneal biomechanical properties identifies over 200 loci providing insight into the genetic etiology of ocular diseases. *Human molecular genetics* **29**, 3154-3164, doi:10.1093/hmg/ddaa155 (2020).

6 Currant, H. *et al.* Genetic variation affects morphological retinal phenotypes extracted from UK Biobank optical coherence tomography images. *PLoS genetics* **17**, e1009497, doi:10.1371/journal.pgen.1009497 (2021).

7 Laville, V. *et al.* Genetic Correlations Between Diabetes and Glaucoma: An Analysis of Continuous and Dichotomous Phenotypes. *American journal of ophthalmology* **206**, 245-255, doi:10.1016/j.ajo.2019.05.015 (2019).

8 Iglesias, A. I. *et al.* Cross-ancestry genome-wide association analysis of corneal thickness strengthens link between complex and Mendelian eye diseases. *Nature communications* **9**, 1864, doi:10.1038/s41467-018-03646-6 (2018).

9 Grassmann, F. *et al.* Genetic pleiotropy between age-related macular degeneration and 16 complex diseases and traits. *Genome medicine* **9**, 29, doi:10.1186/s13073-017-0418-0 (2017).

10 van Koolwijk, L. M. *et al.* Genetic contributions to glaucoma: heritability of intraocular pressure, retinal nerve fiber layer thickness, and optic disc morphology. *Investigative ophthalmology & visual science* **48**, 3669-3676, doi:10.1167/iovs.06-1519 (2007).

11 Asefa, N. G., Neustaeter, A., Jansonius, N. M. & Snieder, H. Heritability of glaucoma and glaucoma-related endophenotypes: Systematic review and meta-analysis. *Survey of ophthalmology* **64**, 835-851, doi:10.1016/j.survophthal.2019.06.002 (2019).

12 Hammond, C. J. *et al.* The heritability of age-related cortical cataract: the twin eye study. *Investigative ophthalmology & visual science* **42**, 601-605 (2001).

13 Warwick, A. & Lotery, A. Genetics and genetic testing for age-related macular degeneration. *Eye (London, England)* **32**, 849-857, doi:10.1038/eye.2017.245 (2018).

14 Chakravarthy, U. & Peto, T. Current Perspective on Age-Related Macular Degeneration. *Jama* **324**, 794-795, doi:10.1001/jama.2020.5576 (2020).

15 Mitchell, P., Liew, G., Gopinath, B. & Wong, T. Y. Age-related macular degeneration. *Lancet* **392**, 1147-1159, doi:10.1016/s0140-6736(18)31550-2 (2018).

16 Fritsche, L. G. *et al.* A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants. *Nature genetics* **48**,

134-143, doi:10.1038/ng.3448 (2016).
17 Liu, Y. C., Wilkins, M., Kim, T., Malyugin, B. & Mehta, J. S. Cataracts. *Lancet (London, England)* **390**, 600-612, doi:10.1016/s0140-6736(17)30544-5 (2017).
18 Choquet, H. *et al.* A large multiethnic GWAS meta-analysis of cataract identifies new risk loci and sex-specific effects. *Nature communications* **12**, 3595, doi:10.1038/s41467-021-23873-8 (2021).
19 Stein, J. D., Khawaja, A. P. & Weizer, J. S. Glaucoma in Adults-Screening, Diagnosis, and Management: A Review. *Jama* **325**, 164-174, doi:10.1001/jama.2020.21899 (2021).
20 Jonas, J. B. *et al.* Glaucoma. *Lancet (London, England)* **390**, 2183-2193, doi:10.1016/s0140-6736(17)31469-1 (2017).
21 Khawaja, A. P. *et al.* Genome-wide analyses identify 68 new loci associated with intraocular pressure and improve risk prediction for primary open-angle glaucoma. *Nature genetics* **50**, 778-782, doi:10.1038/s41588-018-0126-8 (2018).
22 Gharahkhani, P. *et al.* Genome-wide meta-analysis identifies 127 open-angle glaucoma loci with consistent effect across ancestries. *Nature communications* **12**, 1258, doi:10.1038/s41467-020-20851-4 (2021).
23 Cuellar-Partida, G. *et al.* Assessment of polygenic effects links primary open-angle glaucoma and age-related macular degeneration. *Scientific reports* **6**, 26885, doi:10.1038/srep26885 (2016).
24 Sergejeva, O., Botov, R., Liutkevičienė, R. & Kriaučiūnienė, L. Genetic factors associated with the development of age-related macular degeneration. *Medicina (Kaunas, Lithuania)* **52**, 79-88, doi:10.1016/j.medici.2016.02.004 (2016).
25 Hu, C. C., Ho, J. D., Lin, H. C. & Kao, L. T. Association between open-angle glaucoma and neovascular age-related macular degeneration: a case-control study. *Eye (London, England)* **31**, 872-877, doi:10.1038/eye.2016.325 (2017).
26 Ratnapriya, R. *et al.* Retinal transcriptome and eQTL analyses identify genes associated with age-related macular degeneration. *Nature genetics* **51**, 606-610, doi:10.1038/s41588-019-0351-9 (2019).
27 Orozco, L. D. *et al.* Integration of eQTL and a Single-Cell Atlas in the Human Eye Identifies Causal Genes for Age-Related Macular Degeneration. *Cell reports* **30**, 1246-1259.e1246, doi:10.1016/j.celrep.2019.12.082 (2020).
28 van Zyl, T. *et al.* Cell atlas of aqueous humor outflow pathways in eyes of humans and four model species provides insight into glaucoma pathogenesis. *Proceedings of the National Academy of Sciences of the United States of America* **117**, 10339-10349, doi:10.1073/pnas.2001250117 (2020).
29 Patel, G. *et al.* Molecular taxonomy of human ocular outflow tissues defined by single-cell transcriptomics. *Proceedings of the National Academy of Sciences of the United States of America* **117**, 12856-12867, doi:10.1073/pnas.2001896117 (2020).
30 Menon, M. *et al.* Single-cell transcriptomic atlas of the human retina identifies cell types associated with age-related macular degeneration. *Nature communications* **10**, 4902, doi:10.1038/s41467-019-12780-8 (2019).
31 Wang, J. *et al.* ATAC-Seq analysis reveals a widespread decrease of chromatin accessibility in age-related macular degeneration. *Nature communications* **9**, 1364, doi:10.1038/s41467-018-03856-y (2018).

32 Bulik-Sullivan, B. *et al.* An atlas of genetic correlations across human diseases and traits. *Nature genetics* **47**, 1236-1241, doi:10.1038/ng.3406 (2015).
33 Zhang, Q., Privé, F., Vilhjálmsson, B. & Speed, D. Improved genetic prediction of complex traits from individual-level data or summary statistics. *Nature communications* **12**, 4192, doi:10.1038/s41467-021-24485-y (2021).
34 Wallace, D. M., Murphy-Ullrich, J. E., Downs, J. C. & O'Brien, C. J. The role of matricellular proteins in glaucoma. *Matrix biology : journal of the International Society for Matrix Biology* **37**, 174-182, doi:10.1016/j.matbio.2014.03.007 (2014).
35 Little, K., Ma, J. H., Yang, N., Chen, M. & Xu, H. Myofibroblasts in macular fibrosis secondary to neovascular age-related macular degeneration - the potential sources and molecular cues for their recruitment and activation. *EBioMedicine* **38**, 283-291, doi:10.1016/j.ebiom.2018.11.029 (2018).
36 Zhang, J., Qiu, Q., Wang, H., Chen, C. & Luo, D. TRIM46 contributes to high glucose-induced ferroptosis and cell growth inhibition in human retinal capillary endothelial cells by facilitating GPX4 ubiquitination. *Experimental cell research* **407**, 112800, doi:10.1016/j.yexcr.2021.112800 (2021).
37 Goldshmit, Y., Galea, M. P., Wise, G., Bartlett, P. F. & Turnley, A. M. Axonal regeneration and lack of astrocytic gliosis in EphA4-deficient mice. *The Journal of neuroscience : the official journal of the Society for Neuroscience* **24**, 10064-10073, doi:10.1523/jneurosci.2981-04.2004 (2004).
38 Kozulin, P., Natoli, R., O'Brien, K. M., Madigan, M. C. & Provis, J. M. Differential expression of anti-angiogenic factors and guidance genes in the developing macula. *Molecular vision* **15**, 45-59 (2009).
39 Zeng, Z. *et al.* Downregulation of CKS1B restrains the proliferation, migration, invasion and angiogenesis of retinoblastoma cells through the MEK/ERK signaling pathway. *International journal of molecular medicine* **44**, 103-114, doi:10.3892/ijmm.2019.4183 (2019).
40 Francis, P. J. The influence of genetics on response to treatment with ranibizumab (Lucentis) for age-related macular degeneration: the Lucentis Genotype Study (an American Ophthalmological Society thesis). *Transactions of the American Ophthalmological Society* **109**, 115-156 (2011).
41 Zhou, H. *et al.* Glia-to-Neuron Conversion by CRISPR-CasRx Alleviates Symptoms of Neurological Disease in Mice. *Cell* **181**, 590-603.e516, doi:10.1016/j.cell.2020.03.024 (2020).
42 Yuan, F., Wang, M., Jin, K. & Xiang, M. Advances in Regeneration of Retinal Ganglion Cells and Optic Nerves. *International journal of molecular sciences* **22**, doi:10.3390/ijms22094616 (2021).
43 You, M., Rong, R., Zeng, Z., Xia, X. & Ji, D. Transneuronal Degeneration in the Brain During Glaucoma. *Frontiers in aging neuroscience* **13**, 643685, doi:10.3389/fnagi.2021.643685 (2021).
44 Sullivan, R. K., Woldemussie, E. & Pow, D. V. Dendritic and synaptic plasticity of neurons in the human age-related macular degeneration retina. *Investigative ophthalmology & visual science* **48**, 2782-2791, doi:10.1167/iovs.06-1283 (2007).
45 Zhang, T. *et al.* Human macular Müller cells rely more on serine biosynthesis to combat

oxidative stress than those from the periphery. *eLife* **8**, doi:10.7554/eLife.43598 (2019).
46 García-Bermúdez, M. Y. *et al.* Glial Cells in Glaucoma: Friends, Foes, and Potential Therapeutic Targets. *Frontiers in neurology* **12**, 624983, doi:10.3389/fneur.2021.624983 (2021).
47 Ramírez, J. M., Ramírez, A. I., Salazar, J. J., de Hoz, R. & Triviño, A. Changes of astrocytes in retinal ageing and age-related macular degeneration. *Experimental eye research* **73**, 601-615, doi:10.1006/exer.2001.1061 (2001).
48 Fu, D. J. *et al.* Insights From Survival Analyses During 12 Years of Anti-Vascular Endothelial Growth Factor Therapy for Neovascular Age-Related Macular Degeneration. *JAMA ophthalmology* **139**, 57-67, doi:10.1001/jamaophthalmol.2020.5044 (2021).
49 Voigt, A. P. *et al.* Single-cell transcriptomics of the human retinal pigment epithelium and choroid in health and macular degeneration. *Proceedings of the National Academy of Sciences of the United States of America* **116**, 24100-24107, doi:10.1073/pnas.1914143116 (2019).
50 Klein, B. E., Klein, R., Lee, K. E., Knudtson, M. D. & Tsai, M. Y. Markers of inflammation, vascular endothelial dysfunction, and age-related cataract. *American journal of ophthalmology* **141**, 116-122, doi:10.1016/j.ajo.2005.08.021 (2006).
51 Bukhari, S. M. *et al.* Microvascular endothelial function and severity of primary open angle glaucoma. *Eye (London, England)* **30**, 1579-1587, doi:10.1038/eye.2016.185 (2016).
52 Su, W. W. *et al.* Glaucoma is associated with peripheral vascular endothelial dysfunction. *Ophthalmology* **115**, 1173-1178.e1171, doi:10.1016/j.ophtha.2007.10.026 (2008).
53 Buniello, A. *et al.* The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019. *Nucleic acids research* **47**, D1005-d1012, doi:10.1093/nar/gky1120 (2019).
54 Sudlow, C. *et al.* UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. *PLoS medicine* **12**, e1001779, doi:10.1371/journal.pmed.1001779 (2015).
55 Canela-Xandri, O., Rawlik, K. & Tenesa, A. An atlas of genetic associations in UK Biobank. *Nature genetics* **50**, 1593-1599, doi:10.1038/s41588-018-0248-z (2018).
56 Zheng, J. *et al.* LD Hub: a centralized database and web interface to perform LD score regression that maximizes the potential of summary level GWAS data for SNP heritability and genetic correlation analysis. *Bioinformatics (Oxford, England)* **33**, 272-279, doi:10.1093/bioinformatics/btw613 (2017).
57 Leslie, R., O'Donnell, C. J. & Johnson, A. D. GRASP: analysis of genotype-phenotype results from 1390 genome-wide association studies and corresponding open access database. *Bioinformatics (Oxford, England)* **30**, i185-194, doi:10.1093/bioinformatics/btu273 (2014).
58 Kamat, M. A. *et al.* PhenoScanner V2: an expanded tool for searching human genotype-phenotype associations. *Bioinformatics (Oxford, England)* **35**, 4851-4853, doi:10.1093/bioinformatics/btz469 (2019).
59 Mailman, M. D. *et al.* The NCBI dbGaP database of genotypes and phenotypes. *Nature genetics* **39**, 1181-1186, doi:10.1038/ng1007-1181 (2007).
60 Kurki, M. I. *et al.* FinnGen: Unique genetic insights from combining isolated population

and national health register data. *medRxiv*, 2022.2003.2003.22271360, doi:10.1101/2022.03.03.22271360 (2022).

61 Hemani, G. *et al.* The MR-Base platform supports systematic causal inference across the human phenome. *eLife* **7**, doi:10.7554/eLife.34408 (2018).

62 Sherry, S. T. *et al.* dbSNP: the NCBI database of genetic variation. *Nucleic acids research* **29**, 308-311, doi:10.1093/nar/29.1.308 (2001).

63 Pickrell, J. K. *et al.* Detection and interpretation of shared genetic influences on 42 human traits. *Nature genetics* **48**, 709-717, doi:10.1038/ng.3570 (2016).

64 Bhattacharjee, S. *et al.* A subset-based approach improves power and interpretation for the combined analysis of genetic association studies of heterogeneous traits. *American journal of human genetics* **90**, 821-835, doi:10.1016/j.ajhg.2012.03.015 (2012).

65 Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics (Oxford, England)* **26**, 2190-2191, doi:10.1093/bioinformatics/btq340 (2010).

66 Andreassen, O. A. *et al.* Improved detection of common variants associated with schizophrenia and bipolar disorder using pleiotropy-informed conditional false discovery rate. *PLoS genetics* **9**, e1003455, doi:10.1371/journal.pgen.1003455 (2013).

67 Purcell, S. *et al.* PLINK: a tool set for whole-genome association and population-based linkage analyses. *American journal of human genetics* **81**, 559-575, doi:10.1086/519795 (2007).

68 Auton, A. *et al.* A global reference for human genetic variation. *Nature* **526**, 68-74, doi:10.1038/nature15393 (2015).

69 de Leeuw, C. A., Mooij, J. M., Heskes, T. & Posthuma, D. MAGMA: generalized gene-set analysis of GWAS data. *PLoS computational biology* **11**, e1004219, doi:10.1371/journal.pcbi.1004219 (2015).

70 Wang, S. K. *et al.* Single-cell multiome of the human retina and deep learning nominate causal variants in complex eye diseases. *bioRxiv*, 2022.2003.2009.483684, doi:10.1101/2022.03.09.483684 (2022).

71 Zheng, G. X. *et al.* Massively parallel digital transcriptional profiling of single cells. *Nature communications* **8**, 14049, doi:10.1038/ncomms14049 (2017).

72 Hao, Y. *et al.* Integrated analysis of multimodal single-cell data. *Cell* **184**, 3573-3587.e3529, doi:10.1016/j.cell.2021.04.048 (2021).

73 Durinck, S., Spellman, P. T., Birney, E. & Huber, W. Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt. *Nature protocols* **4**, 1184-1191, doi:10.1038/nprot.2009.97 (2009).

74 Strunz, T. *et al.* A mega-analysis of expression quantitative trait loci in retinal tissue. *PLoS genetics* **16**, e1008934, doi:10.1371/journal.pgen.1008934 (2020).

75 Giambartolomei, C. *et al.* Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. *PLoS genetics* **10**, e1004383, doi:10.1371/journal.pgen.1004383 (2014).

76 Cherry, T. J. *et al.* Mapping the cis-regulatory architecture of the human retina reveals noncoding genetic variation in disease. *Proceedings of the National Academy of Sciences of the United States of America* **117**, 9001-9012, doi:10.1073/pnas.1922501117 (2020).

77 Fulco, C. P. *et al.* Activity-by-contact model of enhancer-promoter regulation from thousands of CRISPR perturbations. *Nature genetics* **51**, 1664-1669, doi:10.1038/s41588-019-0538-0 (2019).

78 Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. *Nature methods* **9**, 357-359, doi:10.1038/nmeth.1923 (2012).

79 Weissbrod, O. *et al.* Functionally informed fine-mapping and polygenic localization of complex trait heritability. *Nature genetics* **52**, 1355-1363, doi:10.1038/s41588-020-00735-5 (2020).

80 Wang, G., Sarkar, A., Carbonetto, P. & Stephens, M. A simple new approach to variable selection in regression, with application to genetic fine mapping. *Journal of the Royal Statistical Society: Series B (Statistical Methodology)* **82**, 1273-1300 (2020).

81 Szklarczyk, D. *et al.* STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. *Nucleic acids research* **47**, D607-d613, doi:10.1093/nar/gky1131 (2019).

82 Wishart, D. S. *et al.* DrugBank: a comprehensive resource for in silico drug discovery and exploration. *Nucleic acids research* **34**, D668-672, doi:10.1093/nar/gkj067 (2006).

83 Freshour, S. L. *et al.* Integration of the Drug-Gene Interaction Database (DGIdb 4.0) with open crowdsource efforts. *Nucleic acids research* **49**, D1144-d1151, doi:10.1093/nar/gkaa1084 (2021).

84 Shannon, P. *et al.* Cytoscape: a software environment for integrated models of biomolecular interaction networks. *Genome research* **13**, 2498-2504, doi:10.1101/gr.1239303 (2003).

Figure legends

Figure1. Genetic pleiotropy of ocular disorders at the genomic level and regional level.

a. Multi-state models for the role of one ocular disease in transitions to other two diseases. **b.** Epidemiological and genetic correlations between AMD, cataract and glaucoma. c. Genetic correlations of AMD, cataract and glaucoma estimated by LDSC, the black star indicated significant results. **d.** Chromosome graphics showing the pleiotropic regions assessed by gwas-pw. A partial enlarged view shows the pleiotropic region resided in chromosome 15 which overlapped with one locus identified by meta-analysis. Different color dots represent the posterior probability of trait pairs (red: AMD-cataract; blue: AMD-glaucoma; green: cataract-glaucoma). The dashed line represents the predictive threshold of posterior probability larger than 0.6.

Figure 2. The pleiotropic loci of ocular phenotypes as well as trait-associated cell types.

a. Circular Manatten plot of the meta-analysis results using one sided ASSET. The orange triangles denote the lead SNPs of pleiotropic loci identified by three meta-analysis methods. The texts beside triangles show the nearest genes of these loci. **b.** The significance of various cell types from two software in the cell-type trait association analysis. The significant cell types after Benjamini-Hochberg correction were highlighted. **c.** Locus compare plots of SNP rs3766916 with eQTL gene TRIM46. **d.** Locuszoom plots of one-sided ASSET associations and posterior probability of causality for variants around risk SNP rs4845712 which overlaps with *EFNA3* enhancer predicted by Activity-by-Contact (ABC) model and retinal HiChIP data. The overlapped open chromatin peaks of 13 retinal cell types were shown in the middle.

Figure 3. Integration with retinal eQTL data and enhancer regions prioritizes causal genes.

a. Locuszoom plots of one-sided ASSET associations and posterior probability of causality for

variants around risk SNP rs10898526 which overlaps with *ME3* predicted enhancer. **b.** Locuszoom plots of one-sided ASSET associations and posterior probability of causality for variants around risk SNP rs351973 which reside in one of the HiChIP anchors. The overlapped open chromatin peaks of 13 retinal cell types were shown in the middle.

Figure 4. Drug repositioning of putative genes and selected enriched term network of disease-risk genes and drug-targeted genes of AMD and glaucoma.

a. Gene ontology pathway enrichment analysis of pleiotropic causal genes. **b.** Protein-protein interaction (PPI) network of causal genes. The red text with larger nodes indicated the pleiotropic gene in three diseases while the purple text indicated pleiotropic genes in two diseases. The thickness of edges represents the strength of evidence. **c. & d.** PPI networks using disease-risk genes and drug-targeted genes. The nodes in light blue ellipses represent the lateral drug target genes.

a


Start of follow-up (free of cataract and AMD)
Transition A HR=2.89 (2.74, 3.04)
Cataract
Transition C HR=1.54 (1.18, 2.00)
Transition B HR=0.64 (0.53, 0.77)
AMD
Start of follow-up (free of cataract and AMD)
Transition A HR=1.41 (1.16, 1.71)
AMD
Transition C HR=3.01 (2.86, 3.17)
Transition B HR=1.05 (0.82, 1.33)
Cataract
Start of follow-up (free of glaucoma and AMD)
Transition A HR=1.77 (1.61, 1.93)
Glaucoma
Transition C HR=1.64 (1.51, 1.78)
Transition B HR=1.42 (1.04, 1.94)
AMD
Start of follow-up (free of glaucoma and AMD)
Transition A HR=1.65 (1.52, 1.77)
AMD
Transition C HR=1.75 (1.60, 1.92)
Transition B HR=1.28 (0.90, 1.83)
Glaucoma
Start of follow-up (free of cataract and glaucoma)
Transition A HR=1,60 (1.43, 1.79)
Cataract
Transition C HR=1.71 (1.16, 2.51)
Transition B HR=1.05 (0.66, 1.66)
Glaucoma
Start of follow-up (free of cataract and glaucoma)
Transition A HR=1.47 (1.02, 2.10)
Glaucoma
Transition C HR=1.62 (1.45, 1.82)
Transition B HR=0.88 (0.50, 1.55)
Cataract

b


Hazard ratio
LDSC
LDAK
Glaucoma
AMD
Cataract
1.49
1.82
-0.186
-0.206
0.226
0.225
1.78
2.85
0.209
0.191
1.57
1.67

c


Glaucoma.1
Glaucoma.finngen
AMD.1
AMD.2
AMD.finngen
Cataract.1
Cataract.2
Cataract.finngen
1
0.8
0.6
0.4
0.2
0
-0.2
-0.4
-0.6
-0.8
-1

d


chr1
1q42.12
chr3
3q26.33
chr5
5q14.3
chr9
9p21.3
chr11
11q13.2
11q14.2
chr12
12q13.2
12q24.11
chr15
15q12
chr16
16q22.1
chr17
17q25.3
0bp
50Mb
100Mb
150Mb
200Mb
250Mb
Length (bp)
AMD_cataract
AMD_glaucoma
cataract_glaucoma
Posterior probability
1.0
0.8
0.6
0.4
0.2
0.0
chr15
20Mb
25Mb
30Mb
35Mb
40Mb
45Mb
50Mb
55Mb
Length (bp)


a
Chr1
Chr2
Chr3
Chr4
Chr5
Chr6
Chr7
Chr8
Chr9
Chr10
Chr11
Chr12
Chr13
Chr14
Chr15
Chr16
Chr17
Chr18
Chr19
Chr20
Chr21
Chr22
EFNA3
LPPR3
TSC22D2
HERC2
CDKN2B-AS1
LINC00461
ME3
TYR
CAV2
RUNX2
0
1
1120
2239
3358
4477
5596
6715
7834
8953
>8953
b
scRNA (MAGMA)
scATAC (LDSC)
Muller cells
Astrocyte
Microglia
Horizontal
Rods
All−amacrine
Cones
Rod bipolar
Gly−amacrine
RGCs
ON−cone bipolar
GABA−amacrine
OFF−cone bipolar
−Log10(P−value)
−Log10(P−value)
c
rs3766916
rs12047986
r2
0.8
0.6
0.4
0.2
TRIM46
GWAS −Log10(P)
eQTL −Log10(P)
rs3766916
rs4845712
GWAS −Log10(P)
chr1 (Mb)
rs3766916
rs4845712
eQTL −Log10(P)
chr1 (Mb)
d
Finemapping
r2
0.8
0.6
0.4
0.2
rs4845712
Posterior probability
Recombination rate (cM/Mb)
All-amacrine
Astrocyte
Cones
GABA-amacrine
Gly-amacrine
Horizontal
Microglia
Muller cells
OFF-cone bipolar
ON-cone bipolar
RGCs
Rod
Rod bipolar
H3K27ac HiChIP enhancer loops
ABC model
Genes
FLAD1
ADAM15
DPM3
MUC1
THBS3
PBXIP1
SHC1
MIR4258
ZBTB7B
DCST1
EFNA3
SLC50A1
TRIM46
MIR92B
PMVK
PYGO2
CKS1B
LENEP
DCST2
DCST1-AS1
EFNA4
EFNA1
KRTCAP2
MTX1
Position on chr1 (Mb)


a
b
ASSET
rs10898526
rs351973
-Log10(p-value)
Recombination rate (cM/Mb)
r2
0.8
0.6
0.4
0.2
Finemapping
Posterior probability
All-amacrine
Astrocyte
Cones
GABA-amacrine
Gly-amacrine
Horizontal
Microglia
Muller cells
OFF-cone bipolar
ON-cone bipolar
RGCs
Rod
Rod bipolar
ABC model enhancer
H3K27ac HiChIP loops
Genes
ME3
PRSS23
MIR3187
PLPPR3
PRSS57
MISP
MIR4745
PRTN3
CFD
R3HDM4
RNF126
PTBP1
ELANE
MED16
ARID3A
FSTL3
PALM
AZU1
KISS1R
Position on chr11 (Mb)
Position on chr19 (Mb)


a
2.4
2.2
2.0
1.8
1.6
Cell surface receptor signaling pathway
Cellular protein modification process
ERBB2 signaling pathway
Nerve development
Peptidyl−amino acid modification
Positive regulation of cell population proliferation
Positive regulation of cellular metabolic process
Positive regulation of cellular protein metabolic process
Positive regulation of nitrogen compound metabolic process
Positive regulation of phosphatidylinositol 3−kinase signaling
Positive regulation of protein modification process
Regulation of cellular protein metabolic process
Regulation of nitrogen compound metabolic process
Regulation of protein modification process
Transmembrane receptor protein tyrosine kinase signaling pathway
Gene number
5
10
15
20
-log10(FDR)
1.6
1.8
2.0
2.2
b
SUPT3H
PYGO2
KAT2A
KAT2B
SKP1
CDK2
CKS1B
SKP2
ADAM15
PBXIP1
CAV2
ERBB2
SHC1
TYR
KDR
ERBB3
IGF1R
EFNA4
EFNA3
c
EFNA4
Aflibercept
EFNA3
VEGFA
SHC1
PBXIP1
ADAM15
Pleiotropic genes
AMD drug genes
d
TSD22D2
GABRB3
KISS1R
TYR
Pilocarpine
GABRA5
CHRNB2
NTRK1
CAV2
SHC1
EFNA3
EFNA4
RUSC1
PBXIP1
ADAM15
Pleiotropic genes
Glaucoma drug genes